LYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.72 USD | -8.70% |
|
-9.06% | -9.92% |
| Mar. 22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
| Mar. 21 | Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 147.4 | 56.7 | 99.94 | 275.4 | 282 | - | - |
| Enterprise Value (EV) 1 | 147.4 | 56.7 | 99.94 | 275.4 | 282 | 282 | 282 |
| P/E ratio | -4.4 x | -1.3 x | -1.72 x | -4.16 x | -4.67 x | -4.24 x | -3.6 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 199 x | 73.3 x | 177 x | 204 x | 361 x | 10.6 x |
| EV / Revenue | - | 199 x | 73.3 x | 177 x | 204 x | 361 x | 10.6 x |
| EV / EBITDA | -6.66 x | -1.33 x | -1.85 x | - | -4.74 x | -3.04 x | - |
| EV / FCF | -6.43 x | - | -2.29 x | -4.28 x | -4.27 x | -3.66 x | -3.24 x |
| FCF Yield | -15.6% | - | -43.6% | -23.4% | -23.4% | -27.4% | -30.9% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 12,927 | 13,005 | 31,827 | 52,563 | 59,743 | - | - |
| Reference price 2 | 11.40 | 4.360 | 3.140 | 5.240 | 4.720 | 4.720 | 4.720 |
| Announcement Date | 3/9/21 | 3/9/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.285 | 1.363 | 1.558 | 1.379 | 0.7815 | 26.48 |
| EBITDA 1 | - | -22.11 | -42.61 | -53.92 | - | -59.51 | -92.76 | - |
| EBIT 1 | - | -22.21 | -43.62 | -54.99 | -67.12 | -71.16 | -83.53 | -100.3 |
| Operating Margin | - | - | -15,303.51% | -4,034.48% | -4,308.09% | -5,159.95% | -10,687.84% | -378.69% |
| Earnings before Tax (EBT) 1 | - | -22.13 | -43.51 | -55.26 | -62.62 | -68.49 | -82.05 | -98.46 |
| Net income 1 | - | -22.13 | -43.51 | -55.28 | -62.68 | -68.59 | -82.06 | -98.46 |
| Net margin | - | - | -15,267.72% | -4,055.61% | -4,023.11% | -4,973.86% | -10,500.87% | -371.76% |
| EPS 2 | -2.370 | -2.590 | -3.350 | -1.830 | -1.260 | -1.010 | -1.113 | -1.310 |
| Free Cash Flow 1 | - | -22.92 | - | -43.55 | -64.35 | -66 | -77.15 | -87 |
| FCF margin | - | - | - | -3,195.08% | -4,130.36% | -4,786.08% | -9,872.04% | -328.49% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/6/20 | 3/9/21 | 3/9/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.014 | 0.271 | 5.367 | 0.407 | 0.359 | 0.011 | 0.41 | 0.458 | 0.544 | 0.146 | 0.3458 | 0.3465 | 0.3472 | 0.3362 | - |
| EBITDA | - | - | - | - | -14.55 | -13.62 | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.08 | -13.64 | -7.026 | -14.52 | -14.83 | -13.84 | -17.31 | -16.5 | -16.83 | -16.48 | -17.54 | -18.07 | -18.58 | -19.25 | -19 |
| Operating Margin | -79,150% | -5,032.47% | -130.91% | -3,567.08% | -4,129.81% | -125,809.09% | -4,222.68% | -3,603.28% | -3,093.2% | -11,285.62% | -5,071.91% | -5,214.6% | -5,353.11% | -5,727.46% | - |
| Earnings before Tax (EBT) 1 | -11.06 | -13.62 | -7.012 | -14.48 | -14.77 | -14.22 | -16.24 | -15.61 | -15.64 | -15.14 | -16.86 | -17.49 | -18.05 | -18.58 | -19 |
| Net income 1 | -11.06 | -13.62 | -7.012 | -14.48 | -14.77 | -14.24 | -16.26 | -15.62 | -15.65 | -15.16 | -16.87 | -17.49 | -18.06 | -18.58 | -19 |
| Net margin | -78,964.29% | -5,024.72% | -130.65% | -3,558.72% | -4,113.09% | -129,409.09% | -3,964.63% | -3,410.04% | -2,877.02% | -10,380.82% | -4,877.6% | -5,048.2% | -5,201.6% | -5,526.61% | - |
| EPS 2 | -0.8500 | -1.050 | -0.5400 | -0.4300 | -0.4000 | -0.3600 | -0.4400 | -0.3600 | -0.2700 | -0.1900 | -0.2740 | -0.2520 | -0.2500 | -0.2540 | -0.2400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/9/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/29/23 | 5/12/23 | 8/8/23 | 11/7/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -22.9 | - | -43.5 | -64.4 | -66 | -77.2 | -87 |
| ROE (net income / shareholders' equity) | - | -54.1% | -80% | -96.1% | -73.7% | -63.1% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | -2.460 | -1.990 | -1.430 | -1.270 | -0.8300 | -1.470 | - |
| Capex 1 | - | 1.78 | 3.39 | 0.16 | 1.05 | 0.63 | 0.7 | 0.75 |
| Capex / Sales | - | - | 1,187.72% | 12.03% | 67.2% | 45.36% | 89.7% | 2.84% |
| Announcement Date | 3/6/20 | 3/9/21 | 3/9/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.72
USD
Average target price
12
USD
Spread / Average Target
+154.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.92% | 282M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- LYRA Stock
- Financials Lyra Therapeutics, Inc.
